- BioMark (BUX) recognizes and supports Lung Cancer Awareness Month
- Throughout November and beyond, BioMark will be posting relevant short articles related to this fatal disease in different social media
- Last year, lung cancer remained the leading cause of cancer death, with an estimated 1.8 million deaths accounting for 18 per cent of all cancer deaths
- Low socioeconomic populations experience greater environmental exposures and subsequent increased lung cancer incidence and mortality
- BioMark Diagnostics Inc. (BUX) is down 4.17 per cent, trading at C$0.23 at 9:30 am ET
BioMark Diagnostics Inc. (BUX) recognizes and wants to raise awareness of the challenges that come from a diagnosis of lung cancer.
Strides are being made in both the early diagnosis and therapeutic intervention that will improve the treatment journey for patients.
Throughout November and beyond, BioMark will be posting relevant short articles related to this fatal disease on different social media channels. The campaign aims to encourage both men and women to know their risks for lung cancer and to consider annual screenings to gain an advantage on the disease through earlier diagnosis.
“Since 2007, our mission and team commitment remain the same. Develop and commercialize innovative technologies that increase the accuracy of early-stage diagnosis of cancers,” says Rashid Bux, President and CEO.
“Our goal this month is not only to share information but to recognize and support individuals and groups who have helped to make a difference for lung cancer patients, caregivers, family and friends,” added Bux.
Last year, lung cancer remained the leading cause of cancer death, with an estimated 1.8 million deaths accounting for 18 per cent of all cancer deaths. There is also an imperative need to better understand and address disparities in ethnic and socioeconomic inequities in lung cancer that contribute to cancer incidence and mortality.
Low socioeconomic populations experience greater environmental exposures and subsequent increased lung cancer incidence and mortality. Similarly, rurality leads to further disparities, as black individuals in rural areas have greater lung cancer incidence than those in urban areas.
BioMark is developing proprietary, non-invasive, and accurate cancer diagnostic solutions which can help detect, monitor, and assess treatment for cancer early and cost-effectively. The technology can also be used for measuring response to treatment and potentially for serial monitoring of cancer survivors.
BioMark Diagnostics Inc. (BUX) is down 4.17 per cent, trading at C$0.23 at 9:30 am ET.
